Add to ORKGObjective: To evaluate the effectiveness of GCSF as a secondary preventive adjunct to chemotherapy in the gynaecologic cancer patients who previously had grade 3-4 neutropenia or leucopenia from chemotherapy. Material and Method: We retrospectively reviewed the medical records of 94 chemotherapeutic cycles with GCSF as secondary prophylaxis in 29 patients with gynaecologic malignancy between January 1996 an
Background. We evaluated efficacy and safety of recombinant granulocyte-colony stimulating factor (r...
Bakground: Neutropenia and infections are the most restrictive side effects in chemotherapy applicat...
Introduction: Chemotherapy-induced neutropenia, the depth and length of which are correlated to the ...
After informed consent, 86 patients with advanced cancer undergoing potentially myelosuppressive cyt...
A number of cytokines have been used in the past two decades to reduce the complications of neutrope...
Purpose: Pegfilgrastim was introduced over a decade ago. Other long-acting granulocyte colony-stimul...
Pegfilgrastim was introduced over a decade ago. Other long-acting granulocyte colony-stimulating fac...
Objectives: Prophylaxis with granulocyte colony-stimulating factor (G-CSF) reduces the severity of c...
Purpose Early breast cancer is commonly treated with anthracyclines and taxanes. However, combining ...
Doxorubicin and cyclophosphamide (AC)-based chemotherapy has been a standard regimen for early-stage...
PURPOSE: Early breast cancer is commonly treated with anthracyclines and taxanes. However, combining...
Chemotherapy induced neutropenic fever requires a hospitalization in 20-30 % of cases and is then as...
The clinical evaluation of human granulocyte colony-stimulating factor (G-CSF) in 38 patients treate...
In this study, nine patients with non-Hodgkin's lymphoma (n=6) and Hodgkin's disease (n=3) receiving...
It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose we...
Background. We evaluated efficacy and safety of recombinant granulocyte-colony stimulating factor (r...
Bakground: Neutropenia and infections are the most restrictive side effects in chemotherapy applicat...
Introduction: Chemotherapy-induced neutropenia, the depth and length of which are correlated to the ...
After informed consent, 86 patients with advanced cancer undergoing potentially myelosuppressive cyt...
A number of cytokines have been used in the past two decades to reduce the complications of neutrope...
Purpose: Pegfilgrastim was introduced over a decade ago. Other long-acting granulocyte colony-stimul...
Pegfilgrastim was introduced over a decade ago. Other long-acting granulocyte colony-stimulating fac...
Objectives: Prophylaxis with granulocyte colony-stimulating factor (G-CSF) reduces the severity of c...
Purpose Early breast cancer is commonly treated with anthracyclines and taxanes. However, combining ...
Doxorubicin and cyclophosphamide (AC)-based chemotherapy has been a standard regimen for early-stage...
PURPOSE: Early breast cancer is commonly treated with anthracyclines and taxanes. However, combining...
Chemotherapy induced neutropenic fever requires a hospitalization in 20-30 % of cases and is then as...
The clinical evaluation of human granulocyte colony-stimulating factor (G-CSF) in 38 patients treate...
In this study, nine patients with non-Hodgkin's lymphoma (n=6) and Hodgkin's disease (n=3) receiving...
It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose we...
Background. We evaluated efficacy and safety of recombinant granulocyte-colony stimulating factor (r...
Bakground: Neutropenia and infections are the most restrictive side effects in chemotherapy applicat...
Introduction: Chemotherapy-induced neutropenia, the depth and length of which are correlated to the ...